Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing ...

If approved, the pill is expected to be far easier to administer than current injectables — and far easier to manufacture.

Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade ...

The major U.S. equities indexes were mixed at midday Thursday, with the Dow Jones Industrial Average down close to 400 points ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

The stock's fall snapped a three-day winning streak.

Lilly said its investigational once-daily pill achieved positive topline results in a late-stage study evaluating the safety and efficacy of orforglipron compared with a placebo in adults with type 2 ...

Eli Lilly and Company (LLY) is currently at $852.76, up $117.87 or 16.04% --Would be highest close since March 24, 2025, when it closed at $864.90 --On pace for largest percent increase since June 29, ...

The S&P 500 rose 0.13% to close at 5,282.70 on Thursday (April 17) after a volatile trading session, though the index still ...

The UnitedHealth slide weighed heavily on the Dow, which fell 500 points, or 1.3%, Thursday morning.

Most U.S. stocks rose, but the worst drop for UnitedHealth Group in a quarter century kept Wall Street in check.

U.S. stocks are holding steadier in the final day of trading for their holiday-shortened week. The S&P 500 rose 0.2% Thursday ...